CMS launched a voluntary payment model designed to expand Medicare coverage of GLP‑1 weight‑loss drugs by testing alternative payment and reimbursement structures for participating plans and providers. The program, announced by the agency, aims to reduce out‑of‑pocket costs and gather evidence on utilization and budget impacts across Medicare populations. Policymakers and payers will watch enrollment and early utilization data to assess whether the model can scale without destabilizing program spending.